Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central nervous system, conolidine modulates alternate molecular targets. A Science Developments review located that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://friedensreichx518hsg0.iyublog.com/profile